“Production of SARS-CoV-2 pseudotyped viral particles for the evaluation of new therapies against COVID-19”, FAVET, vol. 20, no. Suppl., pp. 44–50, May 2022, doi: 10.14409/favecv.2021.Suppl..44-50.